Multicenter Retrospective Study of Secukinumab Drug Survival in Psoriasis Patients in a Daily Practice Setting: A Long-Term Experience in Spain.
Anti IL-17
Drug survival
Psoriasis
Secukinumab
Journal
Dermatology and therapy
ISSN: 2193-8210
Titre abrégé: Dermatol Ther (Heidelb)
Pays: Switzerland
ID NLM: 101590450
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
28
09
2020
accepted:
04
09
2021
pubmed:
26
9
2021
medline:
26
9
2021
entrez:
25
9
2021
Statut:
ppublish
Résumé
There is limited and conflicting evidence over the real-world drug survival of secukinumab (SEC) in patients with psoriasis, especially in the long term. Our objective was to analyze the short- and long-term survival of SEC (S-SEC) and its predictive factors for the treatment of psoriasis. Patients clinically diagnosed with plaque psoriasis and under treatment with secukinumab (n = 384) in a daily practice setting were analyzed in a retrospective, multicenter study performed in a nationwide cohort and followed up for a period of 2 years. Kaplan-Meier curve was plotted to analyze drug survival time, and log-rank test was performed to compare several groups. Factors related to speed of treatment discontinuation were studied with a Cox regression model. The overall cumulative secukinumab drug survival rates observed at 6, 12, 18, and 24 months were 97.1%, 89.0%, 81.1%, and 74.3%, respectively. Obesity [hazard ratio (HR), 1.809, CI 95% 1.114-2.962; p = 0.004] and previous experience with biological therapies, particularly those who had been treated with ≥ 2 biologicals with different mechanisms of action (HR 3.476, CI 95% 1.875-6.444; p = 0.017) were associated with an early discontinuation, whereas psoriatic arthritis was associated with delayed discontinuation, (HR 0.493, CI 95% 0.265-0.917; p = 0.025). In our study, we found that cumulative secukinumab drug survival for psoriasis patients for the period 6-18 months was in the range of real-world evidence studies. Additionally, we observed a relatively high long-term survival rate at 24 months (74.3%).
Identifiants
pubmed: 34561788
doi: 10.1007/s13555-021-00606-9
pii: 10.1007/s13555-021-00606-9
pmc: PMC8611164
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2207-2215Informations de copyright
© 2021. The Author(s).
Références
Brembilla NC, Senra L, Boehncke W-H. The IL-17 family of cytokines in psoriasis: IL-17A and beyond. Front Immunol. 2018;9:1682.
doi: 10.3389/fimmu.2018.01682
Georgakopoulos JR, Ighani A, Phung M, Yeung J. Drug survival of secukinumab in real-world plaque psoriasis patients: a 52-week, multicenter, retrospective study. J Am Acad Dermatol. 2018;78:1019–20.
doi: 10.1016/j.jaad.2017.11.036
Van den Reek JMPA, van Vugt LJ, van Doorn MBA, van der Kraaij GE, de Kort WJA, Lucker GPH, et al. Initial results of secukinumab drug survival in patients with psoriasis: a multicentre daily practice cohort study. Acta Derm Venereol. 2018;98:648–54.
doi: 10.2340/00015555-2900
Torres T, Balato A, Conrad C, Conti A, Dapavo P, Ferreira, , et al. Secukinumab drug survival in patients with psoriasis: a multicentre, real-world, retrospective study. J Am Acad Dermatol. 2019;81:273–5.
doi: 10.1016/j.jaad.2019.02.031
Palacios-García L, Gómez de Castro C, Mir-Bonafé M, Calzon C, Galache C, Santos-Juanes J. Comment on “Secukinumab drug survival in patients with psoriasis: a multicenter, real-world, retrospective study.” J Am Acad Dermatol. 2019;81:e81–2.
doi: 10.1016/j.jaad.2019.04.072
Augustin M, Jullien D, Martin A, Peralta C. Real-world evidence of secukinumab in psoriasis treatment—a meta-analysis of 43 studies. J Eur Acad Dermatol Venereol. 2020;34:1174–85.
doi: 10.1111/jdv.16180
Carpentieri A, Mascia P, Fornaro M, Beylot-Barry M, Taieb A, Foti C, et al. Effectiveness and safety of secukinumab in patients with moderate-severe psoriasis: a multicenter real-life study. Dermatol Ther. 2020;33:e14044.
doi: 10.1111/dth.14044
Kishimoto M, Komine M, Kamiya K, Sugai J, Mieno M, Ohtsuki M. Drug survival of biologic agents for psoriatic patients in a real-world setting in Japan. J Dermatol. 2020;47:33–40.
doi: 10.1111/1346-8138.15146
Ohata C, Ohyama B, Katayama E, Nakama T. Real-world efficacy and safety of interleukin-17 inhibitors for psoriasis: a single-center experience. J Dermatol. 2020;47:405–8.
doi: 10.1111/1346-8138.15247
Yiu ZZN, Mason KJ, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, et al. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Br J Dermatol. 2020;183:294–302.
doi: 10.1111/bjd.18981
Dapavo P, Siliquini N, Mastorino L, Avallone G, Merli M, Agostini A, et al. Efficacy, safety and drug survival of IL-23, IL-17 and TNF-alpha inhibitors for psoriasis treatment: a retrospective study. J Dermatol Treat. 2021;27:1–20.
doi: 10.1080/09546634.2021.1961998
Iznardo H, Vilarrasa E, López-Ferrer A, Puig L. Real-world drug survival of guselkumab, ixekizumab and secukinumab for psoriasis. Br J Dermatol. 2021. https://doi.org/10.1111/bjd.20416 (Online ahead of print).
doi: 10.1111/bjd.20416
pubmed: 33913516
Mourad AI, Gniadecki R. Biologic drug survival in psoriasis: a systematic review and comparative meta-analysis. Front Med (Lausanne). 2021;7:625755.
doi: 10.3389/fmed.2020.625755
Torres T, Puig L, Vender R, Lynde C, Piaserico S, Carrascosa JM, et al. Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for psoriasis treatment: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol. 2021;22:567–79.
doi: 10.1007/s40257-021-00598-4
Graier T, Salmhofer W, Jonak C, Weger W, Kölli C, Gruber B, et al. Biologic drug survival rates in the era of anti-interleukin-17 antibodies: a time-period-adjusted registry analysis. Br J Dermatol. 2021;184:1094–105.
doi: 10.1111/bjd.19701
Egeberg A, Bryld LE, Skov L. Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2019;81:173–8.
doi: 10.1016/j.jaad.2019.03.048
Chatzimichail G, Günther J, Ständer S, Thaçi D. Drug survival of secukinumab, ustekinumab, and certolizumab pegol in psoriasis: a 2-year, monocentric, retrospective study. J Dermatol Treat. 2021;11:1–5.
doi: 10.1080/09546634.2020.1854428
Egeberg A, Ottosen MB, Gniadecki R, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol. 2018;178:509–19.
doi: 10.1111/bjd.16102
Ruiz-Villaverde R, Rodriguez-Fernandez-Freire L, Galán-Gutierrez M, Armario-Hita JC, Martinez-Pilar L. Drug survival, discontinuation rates, and safety profile of secukinumab in real-world patients: a 152-week, multicenter, retrospective study. Int J Dermatol. 2020;59:633–9.
doi: 10.1111/ijd.14819
Ruiz-Villaverde R, Rodríguez Fernández-Freire L, Galán-Gutiérrez M, Armario-Hita JC, Martinez-Pilar L. Secukinumab: drug survival in clinical practice settings. Actas Dermosifiliogr. 2021;112:361–4.
doi: 10.1016/j.ad.2019.05.018